Sergio Sanchez, MD
Psychiatry · Greer, SCNPI 1912948647
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,450 of the $29,969 with a category attached, or 71.6%. Teva Pharmaceuticals USA, Inc. accounts for 80.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $11,817 and has fallen 53.0% since, to $5,559 in 2025. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $96.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$24K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$535
- Alkermes, Inc.$391
- Sunovion Pharmaceuticals Inc.$363
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$21,45072%
- Travel & lodging$9683%
- Food & beverage$7,52225%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 57 | $24,130 |
| AbbVie(2 entities) | 78 | $1,376 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $1,269 |
| Johnson & Johnson | 16 | $535 |
| Alkermes, Inc. | 10 | $391 |
| Sunovion Pharmaceuticals Inc. | 24 | $363 |
| E.r. Squibb & Sons, L.L.C. | 10 | $322 |
| Vanda Pharmaceuticals Inc. | 16 | $284 |
| Neurocrine Biosciences, Inc. | 6 | $277 |
| Otsuka America Pharmaceutical, Inc. | 12 | $254 |
| Lundbeck LLC | 9 | $137 |
| Ironshore Pharmaceuticals Inc. | 2 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Bausch Health US, LLC | 8 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $114 |
| Axsome Therapeutics, Inc. | 2 | $102 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Eisai Inc. | 1 | $12 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$22,685
- VRAYLAR$591
- LYBALVI$480
- ARISTADA$479
- AUSTEDO$335
- INVEGA SUSTENNA$248
- CAPLYTA$235
- SPRAVATO$232
- COBENFY$232
- Austedo XR$226
- INGREZZA$225
- REXULTI$125
- INVEGA TRINZA$124
- ARISTADA INITIO$120
- Jornay PM 20mg capsules (Bottle of 100)$119
How this compares
$29,969 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,593 |
| Lurasidone Hcl | 39 | $5,086 |
| Fluphenazine Hcl | 20 | $4,429 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $3,714 |
| Quetiapine Fumarate | 91 | $3,430 |
| Haloperidol | 53 | $2,197 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $1,882 |
| Trazodone Hcl | 63 | $1,150 |
| Clonazepam | 105 | $1,115 |
| Hydroxyzine Hcl | 36 | $878 |
| Gabapentin | 36 | $834 |
| Risperidone | 41 | $809 |
| Guanfacine Hcl | 17 | $681 |
| Lamotrigine | 57 | $623 |
| AmantadineAmantadine Hcl | 13 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $11 | $6,59312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Greer
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Nikunjkumar ModiFlorence$133K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.